PDF(Pubmed)
Abstract：
Inflammation plays an essential role and is a common feature in the pathogenesis of many chronic diseases. The exact mechanisms through which sodium-glucose cotransporter-2 (SGLT2) inhibitors achieve their much-acclaimed clinical benefits largely remain unknown. In this review, we detail the systemic and tissue- or organ-specific anti-inflammatory effects of SGLT2 inhibitors using evidence from animal and human studies. We discuss the potential pathways through which SGLT2 inhibitors exert their anti-inflammatory effects, including oxidative stress, mitochondrial, and inflammasome pathways. Finally, we highlight the need for further investigation of the extent of the contribution of the anti-inflammatory effects of SGLT2 inhibition to improvements in cardiometabolic and renal outcomes in clinical studies.
摘要：
炎症在许多慢性疾病的发病机制中起着至关重要的作用并且是共同的特征。钠-葡萄糖协同转运蛋白-2（SGLT2）抑制剂实现其广受好评的临床益处的确切机制在很大程度上仍然未知。在这次审查中,我们利用动物和人体研究的证据,详细介绍了SGLT2抑制剂的全身和组织或器官特异性抗炎作用.我们讨论了SGLT2抑制剂发挥其抗炎作用的潜在途径，包括氧化应激,线粒体，和炎性体通路。最后,我们强调需要进一步研究临床研究中SGLT2抑制的抗炎作用对改善心脏代谢和肾脏结局的贡献程度.
